News from AACR
- U.S. Cancer Mortality Declined 35% Since 1991, AACR Report Shows
Read More
Clinical Practice Guidelines
- The American Society of Hematology has released 10 new recommendations for managing myelofibrosis, published in Blood Advances. They call for extended molecular testing at diagnosis, early transplant referral for higher-risk patients, targeted use of JAK inhibitors, and low-dose aspirin for patients with the JAK2 V617F mutation.
Read More
Reibursement Updates
- This month’s E-Reimbursement Newsletter breaks down recent ACA enrollee cancellations and subsidy changes, updates on Medicare drug price negotiation rounds and MFN pricing models, upcoming 15% annual Medicare lab fee schedule cuts, and the late-released Q4 OPPS drug status and coding changes. Read the full newsletter to stay informed on these shifting regulations and keep your Chargemasters up to date.
Read More
- Starting in the first half of 2027, Aetna will replace separate prior authorizations for chemotherapy, radiation, imaging, and some immunotherapies with one approval early in a patient’s cancer treatment. The change applies to its commercial and Medicare Advantage plans, and Aetna has already started it for Medicaid members in eight states.
Read More
Corporate Member News
Read More
- The FDA approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
Read More
- Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3 EXCALIBER-RRMM Study.
Read More
- The FDA approved approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Read More
- The FDA approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.
Read More
- The FDA approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
Read More
